Takeda’s Dengue vaccine candidate: The Lancet publishes papers from two studies
by Press Release from Outbreak News Today on (#50W06)
Takeda Pharmaceutical Company Limited today announced that The Lancet published two papers related to Takeda's dengue vaccine candidate (TAK-003), reporting on results from the 18-month analysis of the ongoing pivotal Phase 3 Tetravalent Immunization against Dengue Efficacy Study (TIDES) trial and results from the final 48-month analysis of the Phase 2 DEN-204 trial. The analyses are consistent with previously reported safety, immunogenicity and efficacy ["]
The post Takeda's Dengue vaccine candidate: The Lancet publishes papers from two studies appeared first on Outbreak News Today.